Menu Search
Equities

Zhangzhou Pientzehuang Pharmaceutical Co Ltd

600436:SHH

Zhangzhou Pientzehuang Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)197.20
  • Today's Change3.70 / 1.91%
  • Shares traded1.85m
  • 1 Year change-27.23%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy4
Outperform9
Hold2
Sell1
Strong Sell0

Share price forecast in CNY

The 10 analysts offering 12 month price targets for Zhangzhou Pientzhng Phrmctcl Co Ltd have a median target of 263.96, with a high estimate of 358.00 and a low estimate of 170.00. The median estimate represents a 33.85% increase from the last price of 197.20.
High81.5%358.00
Med33.9%263.96
Low-13.8%170.00

Dividends in CNY

In 2023, Zhangzhou Pientzehuang Pharmaceutical Co Ltd reported a dividend of 2.32 CNY, which represents a 85.60% increase over last year. The 9 analysts covering the company expect dividends of 2.26 CNY for the upcoming fiscal year, a decrease of 2.41%.
Div growth (TTM)85.60%
More ▼

Earnings history & estimates in CNY

On Jul 24, 2024, Zhangzhou Pientzhng Phrmctcl Co Ltd reported 2nd quarter 2024 earnings of 1.23 per share.
The next earnings announcement is expected on Oct 21, 2024.
Average growth rate+21.03%
Zhangzhou Pientzhng Phrmctcl Co Ltd reported annual 2023 earnings of 4.64 per share on Jan 30, 2024.
Average growth rate+20.48%
More ▼

Revenue history & estimates in CNY

Zhangzhou Pientzehuang Pharmaceutical., Ltd had 2nd quarter 2024 revenues of 2.48bn. This missed the 3.12bn estimate of the one analyst following the company. This was 5.70% below the prior year's 2nd quarter results.
Average growth rate+2.29%
Zhangzhou Pientzehuang Pharmaceutical., Ltd had revenues for the full year 2023 of 10.06bn. This was 15.69% above the prior year's results.
Average growth rate+15.27%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.